Skip to main content

Improving COgnition in Down syndrome

Project description

New pharmacological treatment for Down’s syndrome

Down’s syndrome (DS) is caused by an extra copy of all or part of the long arm of human chromosome 21. DS causes lifelong cognitive impairments (CIs) which have a significant negative impact on the individuals, their families and society. However, there are currently no approved pharmacological treatments for CIs in people with DS. The EU-funded ICOD project aims to fill this gap by providing a feasibility demonstration of a new therapy for CIs in DS. It will perform first-in-humans and efficacy clinical trials with a new molecular entity (AEF0217), which reverses CIs in animal models of DS. AEF0217 belongs to a new pharmacological class developed by the biotech Aelis Farma: the Signaling Specific Inhibitors of the Cannabinoid (CB1) receptor (CB1-SSi). ICOD will enable a safe and efficacious pharmacological treatment of CIs in people with DS.

Call for proposal

H2020-SC1-2020-Two-Stage-RTD
See other projects for this call

Coordinator

CONSORCIO MAR PARC DE SALUT DE BARCELONA
Address
Paseo Maritim 25-29
08003 Barcelona
Spain
Activity type
Research Organisations
EU contribution
€ 1 448 917

Participants (5)

AELIS FARMA
France
EU contribution
€ 3 353 422,50
Address
Institut Francois Magendie, 146 Rue
33077 Bordeaux
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Associazione Oasi Maria SS. Onlus
Italy
EU contribution
€ 387 500
Address
Via Conte Ruggero 73
94018 Troina
Activity type
Other
INSTITUT JEROME LEJEUNE
France
EU contribution
€ 287 500
Address
31 Rue Galande
75725 Paris
Activity type
Research Organisations
CENTRE HOSPITALIER UNIVERSITAIRE SAINT ETIENNE - CHU
France
EU contribution
€ 256 250
Address

42055 Saint Etienne
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SERVICIO MADRILENO DE SALUD
Spain
EU contribution
€ 256 250
Address
Plaza Carlos Trias Bertran 7
28020 Madrid
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)